Nov 5, 2025 – Trond Atle Smedsrud, CEO Emerging Businesses Aker BioMarine ASA, purchased yesterday 6500 shares in Aker BioMarine ASA at an average price of NOK 85,72 per share through his investment company HAWI Holding AS. The shares were acquired on Oslo Børs. Following the transaction, Smedsrud holds a total of 19 789 shares in Aker BioMarine ASA.
Please see attached primary insider notification form pursuant to the requirements of the Market Abuse Regulation (“MAR”).
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Lars Jacobsen, General Counsel at Aker BioMarine ASA, on Nov 5, 2025 at 09:49 CEST
About Aker BioMarine:
Aker BioMarine is a leading human health and nutrition innovator that develops krill and algae-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.